HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- New therapies, new combinations, same goal
-
- Anticoagulant linked to increased risk for acute coronary events
- ASH opposes mandatory sickle cell trait screening of athletes
- BEAM: Carboplatin/paclitaxel plus bevacizumab failed to improve PFS
- Combo treatment has potential antitumor efficacy against stage IV melanoma
- Exposure to alkylating agents, radiation did not increase likelihood for genetic anomalies among offspring
- Factors associated with obesity in childhood cancer survivors identified
- FDA approves axitinib for renal cell carcinoma
- Hepatitis C infection identified as leading risk factor for HCC
-
- HER-2 breast cancer may benefit from lapatinib/trastuzumab combination therapy
- Incorporating bevacizumab into nasopharyngeal treatment safe, feasible
- Malignancy-risk gene signature developed for early-stage NSCLC
- Men with low-risk prostate cancer may benefit from dutasteride, active surveillance
- Molecular cancerization identified in airway epithelium of smokers
- MRI may be effective in planning nerve-sparing RALP
- Mutation provides insight into genetic cause of familial prostate cancer
- Non-alkylating chemotherapy carried little risk for premature ovarian failure among HL survivors
-
- Noninvasive imaging technique may replace risky brain tumor biopsies
- Pertuzumab/trastuzumab/docetaxel combination linked to prolonged PFS
- Presence of paraben in breast tissue not linked to use of underarm products
- Racial disparities may exist in Hodgkin’s lymphoma incidence
- Recent decline in melanoma mortality isolated to only most educated
- Screening method identified circulating tumor cells in patients with lung cancer
- Sunburn prevention among children important to reducing prevalence of melanoma
- Underlying cause of vemurafenib-induced squamous cell carcinoma discovered
-
- FDA approves first drug for metastatic basal cell carcinoma
- FDA approves imatinib mesylate tablets for GIST
- Discovering the rewards of joining Twitter’s clinical medicine conversation William Wood, MD
- Debasish ‘Debu’ Tripathy, MD, discusses the value of mentors and thinking outside the box
- Calcium and magnesium supplementation may reduce oxaliplatin-induced neurotoxicity Lisa K. Lohr, PharmD, BCPS, BCOP